To include your compound in the COVID-19 Resource Center, submit it here.

PharmaMar reports additional Yondelis data

PharmaMar S.A. said Yondelis trabectedin plus doxorubicin did not significantly improve median overall survival vs. doxorubicin alone in the Phase III OVA-301

Read the full 222 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE